Journal ArticleDOI
Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia.
Robert P. Witherspoon,LD Fisher,Gary Schoch,P.J. Martin,Keith M. Sullivan,Jean E. Sanders,H. J. Deeg,Kristine Doney,D Thomas,Rainer Storb +9 more
Reads0
Chats0
TLDR
It is concluded that recipients of bone marrow transplantation have a low but significant risk of a secondary cancer, particularly non-Hodgkin's lymphoma.Abstract:
To determine the incidence of secondary cancers after bone marrow transplantation, we reviewed the records of all patients at our center who received allogeneic, syngeneic, or autologous transplants for leukemia (n = 1926) or aplastic anemia (n = 320). Thirty-five patients were given a diagnosis of secondary cancer between 1.5 months and 13.9 years (median, 1.0 year) after transplantation. Sixteen patients had non-Hodgkin's lymphomas, 6 had leukemias, and 13 had solid tumors (including 3 each with glioblastoma, melanoma, and squamous-cell carcinoma). There were 1.2 secondary cancers per 100 exposure-years during the first year after transplantation (95 percent confidence interval, 0.7 to 2.0). The rate declined to 0.4 (95 percent confidence interval, 0.2 to 0.7) after one year. The age-adjusted incidence of secondary cancer was 6.69 times higher than that of primary cancer in the general population. In a multivariate model, the predictors (and relative risks) of any type of secondary cancer were acute graft-versus-host disease treated with either antithymocyte globulin (relative risk, 4.2) or an anti-CD3 monoclonal antibody (13.6) and total-body irradiation (3.9). Two additional factors were associated with secondary non-Hodgkin's lymphomas: T-lymphocyte depletion of donor marrow (12.4) and HLA mismatch (3.8). We conclude that recipients of bone marrow transplantation have a low but significant risk of a secondary cancer, particularly non-Hodgkin's lymphoma.read more
Citations
More filters
Journal ArticleDOI
WHO-EORTC classification for cutaneous lymphomas.
Rein Willemze,Elaine S. Jaffe,Günter Burg,Lorenzo Cerroni,Emilio Berti,Steven H. Swerdlow,Elisabeth Ralfkiaer,Sergio Chimenti,José Luis Diaz-Perez,Lyn M. Duncan,Florent Grange,Nancy L. Harris,Werner Kempf,Helmut Kerl,Michael O. Kurrer,Robert Knobler,Nicola Pimpinelli,Chris Sander,Marco Santucci,Wolfram Sterry,Maarten H. Vermeer,Janine Wechsler,Sean Whittaker,Chris J.L.M. Meijer +23 more
TL;DR: The characteristic features of the different primary cutaneous lymphomas and other hematologic neoplasms frequently presenting in the skin are described, and differences with the previous classification schemes are discussed.
Journal ArticleDOI
Solid Cancers after Bone Marrow Transplantation
Rochelle E. Curtis,Philip A. Rowlings,H. Joachim Deeg,Donna A. Shriner,Gérard Socié,Lois B. Travis,Mary M. Horowitz,Robert P. Witherspoon,Robert N. Hoover,Kathleen A. Sobocinski,Joseph F. Fraumeni,John D. Boice,H. Gary Schoch,George E. Sale,Rainer Storb,William D. Travis,Hans-Jochem Kolb,Robert Peter Gale,Jakob Passweg +18 more
TL;DR: The trend toward an increased risk over time after transplantation and the greater risk among younger patients indicate the need for life-long surveillance.
Journal ArticleDOI
Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients.
Lode J. Swinnen,Costanzo-Nordin Mr,Susan G. Fisher,E J O'Sullivan,E J O'Sullivan,M R Johnson,M R Johnson,A L Heroux,A L Heroux,G J Dizikes,G J Dizikes,Roque Pifarré,Roque Pifarré,Richard I. Fisher,Richard I. Fisher +14 more
TL;DR: The addition of OKT3 to the immunosuppressive regimen increases the incidence of post-transplantation lymphoproliferative disorder after cardiac transplantation, and the risk increases sharply after cumulative doses greater than 75 mg.
Journal ArticleDOI
Epstein-Barr Virus and Cancer
TL;DR: EBV was the first human virus to be directly implicated in carcinogenesis and recent advances in antiviral therapeutics, application of monoclonal antibodies, and generation of EBV-specific CTLs are beginning to show promise in the treatment ofEBV-related disorders.
Journal ArticleDOI
Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study.
Rochelle E. Curtis,Lois B. Travis,Philip A. Rowlings,Gérard Socié,Douglas W. Kingma,Peter M. Banks,Elaine S. Jaffe,George E. Sale,Mary M. Horowitz,Robert P. Witherspoon,Donna A. Shriner,Daniel J. Weisdorf,Hans-Jochem Kolb,Keith M. Sullivan,Kathleen A. Sobocinski,Robert Peter Gale,Robert N. Hoover,Joseph F. Fraumeni,H. Joachim Deeg +18 more
TL;DR: It is concluded that factors associated with altered immunity and T-cell regulatory mechanisms are predictors of both early- and late-onset PTLD.
References
More filters
Journal ArticleDOI
The Statistical Analysis of Failure Time Data.
Journal ArticleDOI
Chronic graft-versus-host syndrome in man: A long-term clinicopathologic study of 20 seattle patients
Howard M. Shulman,Keith M. Sullivan,Paul L. Weiden,George B. McDonald,Gary E. Striker,George E. Sale,Robert C. Hackman,Tsoi Ms,Rainer Storb,E. Donnall Thomas +9 more
TL;DR: Three patients had limited chronic GVHD with relatively favorable prognosis characterized by localized skin involvement and/or hepatic disease without chronic aggressive histology, but most patients, however, had extensive disease with a progressive course.
Journal ArticleDOI
Bone-marrow transplantation (first of two parts).
Thomas Ed,Rainer Storb,Clift Ra,Alexander Fefer,F. L. Johnson,Paul E. Neiman,Lerner Kg,Glucksberg H,C. D. Buckner +8 more
Journal ArticleDOI
Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for Leukemia
Rainer Storb,H. Joachim Deeg,John Whitehead,Frederick R. Appelbaum,Patrick G. Beatty,William I. Bensinger,C. Dean Buckner,Reginald A. Clift,Kristine Doney,Vernon T. Farewell,J. D. Hansen,Roger Hill,Lawrence G. Lum,Paul J. Martin,Robert W. McGuffin,Jean E. Sanders,Patricia S. Stewart,Keith M. Sullivan,Robert P. Witherspoon,Gary Yee,E. Donnall Thomas +20 more
TL;DR: It is concluded that the combination of methotrexate and cyclosporine is superior to cyclOSporine alone in the prevention of acute graft versus host disease after marrow transplantation for leukemia, and that this therapy may have a beneficial effect on long-term survival.
Journal ArticleDOI
Marrow Transplantation for Acute Nonlymphocytic Leukemia after Treatment with Busulfan and Cyclophosphamide
George W. Santos,Peter J. Tutschka,Ron Brookmeyer,Rein Saral,William E. Beschorner,Wilma B. Bias,Hayden G. Braine,William H. Burns,Gerald J. Elfenbein,Herbert Kaizer,David Mellits,Lyle L. Sensenbrenner,Robert K. Stuart,A. M. Yeager +13 more
TL;DR: It is concluded that high-dose chemotherapy with busulfan and cyclophosphamide, followed by allogeneic-marrow transplantation, can produce long-term remission of acute leukemia.
Related Papers (5)
Solid Cancers after Bone Marrow Transplantation
Rochelle E. Curtis,Philip A. Rowlings,H. Joachim Deeg,Donna A. Shriner,Gérard Socié,Lois B. Travis,Mary M. Horowitz,Robert P. Witherspoon,Robert N. Hoover,Kathleen A. Sobocinski,Joseph F. Fraumeni,John D. Boice,H. Gary Schoch,George E. Sale,Rainer Storb,William D. Travis,Hans-Jochem Kolb,Robert Peter Gale,Jakob Passweg +18 more
Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study.
Rochelle E. Curtis,Lois B. Travis,Philip A. Rowlings,Gérard Socié,Douglas W. Kingma,Peter M. Banks,Elaine S. Jaffe,George E. Sale,Mary M. Horowitz,Robert P. Witherspoon,Donna A. Shriner,Daniel J. Weisdorf,Hans-Jochem Kolb,Keith M. Sullivan,Kathleen A. Sobocinski,Robert Peter Gale,Robert N. Hoover,Joseph F. Fraumeni,H. Joachim Deeg +18 more